Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Consulting agrmnt
Shuttle Pharmaceuticals Holdings, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Shuttle Pharma to Participate in the Lytham Partners Fall 2023 Investor Conference"
10/05/2023 8-K Entered into consulting agreement
Docs: "for 100,000 shares of stock issuable under the Company’ s 2018 Equity Incentive Plan, with the following vesting schedule: 1/3 of the Restricted Stock Units will vest upon the date of the Effective Date and the remaining Restricted Stock Units will vest annually in one-third increments commencing on the first anniversary date of the date of your appointment to the Board , in accordance with the terms of a separate Restricted Stock Unit Award Agreement between you and the Company. Any unvested Restricted Stock Units will expire upon termination of your service. In addition:"
08/24/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
08/15/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "SHUTTLE PHARMACEUTICALS PROVIDES SECOND QUARTER 2023 CORPORATE UPDATE"
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/03/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "About Shuttle Pharmaceuticals"
06/16/2023 DEF 14C Form DEF 14C - Other definitive information statements:
05/30/2023 SC 13G AFH Holding & Advisory, LLC reports a 9.1% stake in SHUTTLE PHARMACEUTICALS HOLDINGS, INC.
05/26/2023 8-K Results of Operations and Financial Condition, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard...
Docs: "Shuttle Pharmaceuticals Provides First Quarter 2023 Corporate Update"
05/25/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/17/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Shuttle Pharmaceuticals to Participate in the Lytham Partners Spring 2023 Investor Conference"
05/15/2023 NT 10-Q Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB:
05/11/2023 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "EXHIBIT A"
03/22/2023 8-K Quarterly results
03/15/2023 10-K Annual Report for the period ended December 31, 2022
03/09/2023 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
03/06/2023 SC 13G AFH Holding & Advisory, LLC reports a 11.5% stake in SHUTTLE PHARMACEUTICALS HOLDINGS, INC.
02/22/2023 8-K Quarterly results
02/13/2023 DEF 14C Form DEF 14C - Other definitive information statements:
02/02/2023 PRE 14C Form PRE 14C - Other preliminary information statements:
02/02/2023 EFFECT Form EFFECT - Notice of Effectiveness:
02/01/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
01/30/2023 S-1/A Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
01/26/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Shuttle Pharmaceuticals to Present at Lytham Partners Investor Select Conference on January 31"
01/25/2023 S-1 Form S-1 - General form for registration of securities under the Securities Act of 1933:
01/20/2023 D Form D - Notice of Exempt Offering of Securities:
01/12/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...
Docs: "SUBSIDIARY GUARANTY FORM OF WARRANT",
"FORM OF SENIOR SECURED CONVERTIBLE NOTE NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS NOTE NOR THE SECURITIES INTO WHICH THIS NOTE IS CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR AN OPINION OF COUNSEL TO THE HOLDER , IN A FORM REASONABLY ACCEPTABLE TO THE COMPANY, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR UNLESS SOLD OR ELIGIBLE TO BE SOLD PURSUANT TO RULE 144 UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN O...",
"FORM OF WARRANT NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS WARRANT NOR THE SECURITIES INTO WHICH THIS WARRANT IS EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR AN OPINION OF COUNSEL TO THE HOLDER , IN A FORM REASONABLY ACCEPTABLE TO THE COMPANY, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR UNLESS SOLD OR ELIGIBLE TO BE SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FIN...",
"FORM OF SECURITY AGREEMENT This SECURITY AGREEMENT, dated as of January 11, 2023 , is by and among Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation , the Subsidiary Guarantors from time to time party hereto , the holders of the Company’ s Senior Secured Notes, in the original aggregate principal amount of $4,300,000.00 that are signatories hereto , and Alto Opportunity Master Fund, SPC- Segregated Portfolio B, in its capacity as agent for the Purchasers . W I T N E S S E T H: WHEREAS, pursuant to that certain Securities Purchase Agreement dated as of the date hereof, by and among the Company and the Purchasers , the Purchasers have, subject to the terms and conditions of the Purchase Agreement, severally agreed to purchase from the Company the Notes at one or more closings un...",
"FORM OF INTELLECTUAL PROPERTY SECURITY AGREEMENT This Intellectual Property Security Agreement is entered into as of January 11, 2023, by and among SHUTTLE PHARMACEUTICALS HOLDINGS INC., a Delaware corporation , the Subsidiary Guarantors from time to time party hereto , the holders of the Company’ s Senior Secured Notes, in the original aggregate principal amount of $4,300,000.00 that are signatories hereto , and Alto Opportunity Master Fund, SPC- Segregated Portfolio B in its capacity as collateral agent for the Purchasers . RECITALS A. Pursuant to that certain Securities Purchase Agreement dated as of the date hereof, by and among the Company and the Purchasers , the Purchasers have, subject to the terms and conditions of the Purchase Agreement, severally agreed to purchase from the Comp...",
"Agreement”), dated as of January 11, 2023, is made by and among each of the undersigned Guarantors and Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B, as agent for the Holders .",
"NOTICE The undersigned beneficial owner of Registrable Securities hereby elects to include the Registrable Securities owned by it in the Registration Statement. The undersigned hereby provides the following information to the Company and represents and warrants that such information is accurate: QUESTIONNAIRE 1. Name. Full Legal Name of Selling Stockholder: Full Legal Name of Registered Holder above) through which Registrable Securities are held: Full Legal Name of Natural Control Person : 2. Address for Notices to Selling Stockholder: Telephone: ______________________________________ Fax: ____________________________________________ Contact Person: ___________________________________ 3. Broker-Dealer Status: Are you a broker-dealer? Yes ☐ No ☐ 2 If “yes” to Section 3 , did you...",
"Shuttle Pharmaceuticals Announces Private Placement of $4.3 Million of Senior Secured Convertible Note and Warrants ROCKVILLE, Md., Jan. 12, 2023 /PRNewswire/ — Shuttle Pharmaceuticals Holdings, Inc. , a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy while reducing side effects, announced the issuance of a $4.3 million senior secured convertible note and warrant to an institutional investor. Shuttle Pharmaceuticals will receive initial gross proceeds of $4.0 million. In addition, the four-year warrant to purchase up to approximately 1.018 million shares of Shuttle Pharmaceuticals’ common stock at an exercise price of $2.35 per share, upon exercise, would result in additional proceeds of ap..."
12/19/2022 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
12/12/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
12/07/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
11/21/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
11/14/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/01/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Second Amended and Restated Bylaws, as adopted October 28, 2022",
"Form of Director Offer Letter",
"Shuttle Pharmaceuticals Appoints Bette Jacobs to its Board of Directors"
09/22/2022 8-K Entry into a Material Definitive Agreement
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy